Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (16,252)	$ (51,404)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,741	394
Stock-based compensation	8,856	34,230
Change in fair value of liabilities	(441)	2,681
Warrant expense in connection with Merger	0	154
Amortization of debt issuance costs	0	144
Net amortization on securities	971	287
Benefit for deferred taxes	(112)	0
Non-cash operating lease cost	377	378
Non-cash other	(94)	165
Changes in operating assets and liabilities:
Inventory	1,415	(980)
Prepaid expenses and other current assets	(7,677)	(7,147)
Other long-term assets	(30)	(58)
Accounts payable	4,266	5,117
Accrued liabilities	(3,148)	1,114
Deferred revenue	(2,043)	(648)
Operating lease liabilities	(384)	(375)
Earn-out payable	(6,848)	0
Net cash used in operating activities	(19,403)	(15,948)
Investing activities
Purchases of investments	(84,881)	(172,021)
Maturities of investments	82,340	9,500
Proceeds from sales of investments	22,291	0
Investment in website development and internal-use software	(1,197)	(740)
Purchases of property, equipment, and intangible assets	(100)	(63)
Net cash provided by (used in) investing activities	18,453	(163,324)
Financing activities
Pre-closing stock repurchase	0	(22,027)
Proceeds from issuance of common stock upon Merger	0	197,686
Proceeds from PIPE	0	75,000
Payments for transaction costs related to securities issuances	0	(12,794)
Proceeds from repayment of promissory notes associated with vested and unvested shares	0	1,193
Proceeds from exercise of Class A common stock warrants	0	807
Proceeds from exercise of vested and unvested stock options	891	80
Payments for taxes related to net share settlement of equity awards	(404)	0
Payments for earn-out consideration for acquisitions	(23,014)	0
Net cash (used in) provided by financing activities	(22,527)	239,945
Foreign currency effect on cash and cash equivalents	(23)	2
(Decrease) increase in cash, cash equivalents, and restricted cash	(23,500)	60,675
Cash, cash equivalents, and restricted cash at beginning of period	72,640	28,350
Cash, cash equivalents, and restricted cash at end of period	49,140	89,025
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	48,284	88,169
Restricted cash	856	856
Total cash, cash equivalents, and restricted cash	49,140	89,025
Supplemental disclosures of cash flow information
Cash paid for taxes	36	59
Non-cash investing and financing activities
Recapitalization from redeemable convertible preferred stock pre-closing stock repurchase	0	125
Conversion of redeemable convertible preferred stock to common stock	0	249,837
Assumption of Merger warrants liability	0	51,814
Exercise of Private Placement Warrants and Public Warrants	0	20,871
Conversion of Series D preferred stock warrants to Class A common warrants	0	1,160
Vesting of early exercised stock options	$ 38	$ 54